Cardiovascular Outcomes in Older Adults Initiating Empagliflozin vs. DPP-4 Inhibitors and GLP-1 Receptor Agonists: A Subgroup Analysis from the EMPRISE Study

被引：0
|
作者：
Patorno, Elisabetta
Pawar, Ajinkya
Bessette, Lily G.
Najafzadeh, Mehdi
Wexler, Deborah J.
Franklin, Jessica
Deruaz-Luyet, Anouk
Brodovicz, Kimberly
Koeneman, Lisette
Schneeweiss, Sebastian
机构：
来源：
DIABETES | 2020年 / 69卷
关键词：
D O I：
10.2337/db20-133-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
133-LB
引用
收藏
页数：3
相关论文
共 50 条
  • [1] DPP-4 inhibitors and GLP-1 receptor agonists. Cardiovascular effects
    Nauck, M. A.
    El Aziz, M. S. Abd
    Meier, J. J.
    DIABETOLOGE, 2016, 12 (03): : 184 - +
  • [2] Cardiovascular effectiveness of empagliflozin compared to DPP4 inhibitors and to GLP1 receptor agonists: Interim analysis from the empagliflozin comparative effectiveness and safety (EMPRISE) study
    Patorno, Elisabetta
    Pawar, Ajinkya
    Franklin, Jessica
    Najafzadeh, Mehdi
    Wexler, Deborah
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly
    Bessette, Lily
    Schneeweiss, Sebastian
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 119 - 119
  • [3] Cardiovascular Effectiveness of Empagliflozin Compared to DPP4 Inhibitors and to GLP1 Receptor Agonists: Interim Analysis From the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
    Patorno, Elisabetta
    Pawar, Ajinkya
    Franklin, Jessica
    Najafzadeh, Mehdi
    Wexler, Deborah
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly
    Bessette, Lily
    Schneeweiss, Sebastian
    CIRCULATION, 2019, 140
  • [4] GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician?
    Scheen, Andre J.
    ANNALES D ENDOCRINOLOGIE, 2013, 74 (5-6) : 515 - 522
  • [5] Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors
    Donna Shu-Han Lin
    Jen-Kuang Lee
    Wen-Jone Chen
    Diabetologia, 2021, 64 : 1949 - 1962
  • [6] Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors
    Lin, Donna Shu-Han
    Lee, Jen-Kuang
    Chen, Wen-Jone
    DIABETOLOGIA, 2021, 64 (09) : 1949 - 1962
  • [7] Cardiovascular and renal outcomes of GLP-1 receptor agonists vs. DPP-4 inhibitors and basal insulin in type 2 diabetes mellitus: A systematic review and meta-analysis
    Evans, Marc
    Kuodi, Paul
    Akunna, Chisom Joyqueenet
    Mccreedy, Nicole
    Donsmark, Morten
    Ren, Hongye
    Nnaji, Chukwudi A.
    DIABETES & VASCULAR DISEASE RESEARCH, 2023, 20 (06):
  • [8] Global View on Safety and Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors
    Timofte, L.
    Stratmann, B.
    Bojita, M. T.
    Quester, W.
    Tschoepe, D.
    DIABETES STOFFWECHSEL UND HERZ, 2015, 24 (01): : 19 - 27
  • [9] GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes
    Ahrén, B
    Schmitz, O
    HORMONE AND METABOLIC RESEARCH, 2004, 36 (11-12) : 867 - 876
  • [10] Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective
    Brown, Dominique Xavier
    Evans, Marc
    JOURNAL OF NUTRITION AND METABOLISM, 2012, 2012
12345